Helius Medical Technologies, Inc. (NASDAQ:HSDT) Q2 2021 Earnings Conference Call August 12, 2021 5:00 PM ET Company Participants Dane Andreeff – President and Chief Executive Officer Jeff Mathiesen – Chief Financial Officer Conference Call Participants Jeffrey Cohen – Ladenburg Thalmann Gregory Aurand – Noble Capital Markets Operator Please standby. Good evening, ladies and gentlemen and welcome to the Second Quarter of Fiscal Year 2021 Earnings Conference Call for Helius Medical Technologies. At this time, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38445 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of Registrant as specified in its charter) (State or other jurisdiction of incorporation or ...

Helius Medical Technologies, Inc. (NASDAQ:HSDT) Q1 2021 Earnings Conference Call May 17, 2021 5:00 PM ET Company Participants Dane Andreeff - Interim President & Chief Executive Officer Mark Leno - Vice President & General Manager, Canadian Operations Joyce LaViscount - Chief Financial Officer & Chief Operating Officer Conference Call Participants Joe Gomes - Noble Capital Operator Please standby. Good evening ladies and gentlemen and welcome to the First Quarter Fiscal Year 2021 Earnings Conference Call fo ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 For the transition period from to FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-38445 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of Registrant as specified in its charter) Delaware 36-4787690 (State or other jurisdictio ...

Helius Medical Technologies, Inc. (NASDAQ:HSDT) Q4 2020 Earnings Conference Call March 10, 2021 5:00 PM ET Company Participants Dane Andreeff - Interim President & Chief Executive Officer Mark Leno - Vice President & General Manager, Canadian Operations Joyce LaViscount - Chief Financial Officer & Chief Operating Officer Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Anthony Lamport - Lambda Fund Management Mark Palin - AALRR Operator Please standby. Good evening ladies and gentlemen, and w ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the Fiscal Year Ended December 31, 2020 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from _____ to _____ Commission File No. 001-38445 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 36-4787690 (State or other juris ...

Empowering the Healing Process of the Brain Disruptive Technology for Healthcare (NASDAQ:HSDT | TSX:HSM) Legal Disclaimers This presentation contains forward-looking statements, including statements about: uncertainties regarding the FDA regulatory approval process (including the FDA Breakthrough Designation), uncertainties regarding the regulatory approval process in China and Australia, whether the results of our clinical trials will be sufficient to support an FDA, CE Mark or TGA approval of the PoNS™ de ...

Helius Medical Technologies, Inc. (NASDAQ:HSDT) Q3 2020 Earnings Conference Call November 12, 2020 5:45 PM ET Company Participants Dane Andreeff – Interim President and Chief Executive Officer Mark Leno – Vice President and General Manager, Canadian Operations Joyce LaViscount – Chief Financial Officer and Chief Operating Officer Conference Call Participants Operator Please standby. Good evening, ladies and gentlemen, and welcome to the Third Quarter of Fiscal Year 2020 Earnings Conference Call for Helius M ...

FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38445 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of Registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Delaware 36-4787690 (State or other jurisdi ...

The Last Frontier in Healthcare Empowering the Natural Healing Process of the Brain September 2020 LegalDisclaimers This presentation contains forward-looking statements, including statements about: uncertainties regarding the FDA regulatory approval process, whether the results of our clinical trials will be sufficient to support an FDA, CE Mark or TGA approval of the PoNS™ device for marketing or whether the agencies may require that the Company conduct future clinical trials; future economic, competitive ...